U.S. gives full approval to 1st COVID-19 drug for young children

Click to play video: '1 in 4 children develops ‘long COVID’ after infection: study'
1 in 4 children develops ‘long COVID’ after infection: study
WATCH: 1 in 4 children develops 'long COVID' after infection: study – Mar 16, 2022

The U.S. drug regulator on Monday granted the first full approval for treating COVID-19 in children aged 28 days and older to Gilead Sciences Inc’s GILD.O drug remdesivir.

The move comes months after the agency expanded the drug’s emergency use authorization to also include children below 12 years of age weighing at least 3.5 kilograms.

The Food and Drug Administration’s (FDA) decision makes the drug the first approved COVID-19 treatment for children less than 12 years of age, the agency said.

The latest health and medical news emailed to you every Sunday.

The approval is applicable to children who are hospitalized, or have mild-to-moderate disease and are at high risk of severe COVID-19.

(Reporting by Manas Mishra in Bengaluru; Editing by Aditya Soni)


Sponsored content